Skip to content
TrialScanner

NCT06760156

Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym

Phase 2RecruitingINCYCollaborator

Registry record

Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Conditions
Large B-cell Lymphoma
Primary completion
Jan 2027Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT06760156 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT06760156: Tafasitamab and Lenalidomide... | TrialScanner